Tuesday, September 13, 2011
Spinifex Pharmaceuticals Pty Ltd., of Victoria, Australia, presented new animal data related to its candidate EMA401 in diabetic neuropathy at the 21st annual meeting of the Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes on Sept. 11. The data showed that the drug corrected motor and sensory nerve conduction velocity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.